Stockscreener 앱 받기
106.21
0.92%
0.97
전일 마감가:
$105.24
열려 있는:
$105.55
하루 거래량:
1.69M
Relative Volume:
0.74
시가총액:
$20.85B
수익:
$4.58B
순이익/손실:
$870.87M
주가수익비율:
24.15
EPS:
4.3988
순현금흐름:
$945.58M
1주 성능:
-0.62%
1개월 성능:
+9.46%
6개월 성능:
+53.42%
1년 성능:
+46.56%
1일 변동 폭
$104.83
$108.58
1주일 범위
$102.67
$108.58
52주 변동 폭
$53.56
$112.29
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
106.21 | 20.66B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
New Incyte Drug Combo Shows Power Against Deadly Lymphoma - MyChesCo
EC approves label expansion of INCY's lymphoma drug Minjuvi - MSN
Why Incyte (INCY) Stock Is Trading Up Today - Finviz
Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain? - Yahoo Finance
Incyte (INCY) Receives Updated Buy Rating from TD Cowen | INCY S - GuruFocus
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Earnings Preview: What To Expect From Incyte's Report - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH) - The Globe and Mail
Lobbying Update: $70,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Finviz
Incyte Corporation (INCY) Stock Analysis: Strong Revenue Growth and Strategic Developments in the Biotech Sector - DirectorsTalk Interviews
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
ImmunityBio, Xencor Drugs Win E.U. Nods - Los Angeles Business Journal
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
What margin trends mean for Incyte Corporation stockOil Prices & High Return Trade Guides - Улправда
Incyte Corporation $INCY Stock Holdings Increased by Cerity Partners LLC - MarketBeat
Will Incyte Corporation (ICY) stock beat value stocks2025 Analyst Calls & Smart Investment Allocation Tips - ulpravda.ru
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Incyte jumps amid takeover speculation - MSN
Bull of the Day: Eli Lilly (LLY) - Finviz
Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru
Why Incyte Corporation (ICY) stock is a strong buy callGap Down & Expert Approved Momentum Ideas - ulpravda.ru
Can Incyte Corporation stock beat market expectations this quarter2025 Macro Impact & Low Volatility Stock Recommendations - ulpravda.ru
Can Incyte Corporation stock hit analyst price targets2025 Key Lessons & Safe Entry Momentum Stock Tips - ulpravda.ru
Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp EVP & Chief Medical Officer Sells 15,634 Shares - TradingView — Track All Markets
Incyte (INCY) Stock Is Up, What You Need To Know - Finviz
Incyte (NASDAQ:INCY) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma - Indian Pharma Post
Incyte stock hits 52-week high at $109.38 - Investing.com
Incyte Corp. (NASDAQ:INCY) Emerges as a Compelling Value Stock with Strong Fundamentals - Chartmill
INCY: Morgan Stanley Boosts Price Target to $94 in Latest Analys - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Dow, S&P 500 Hit Record Highs; Guardant, Intuitive Surgical, Incyte In Focus - Investor's Business Daily
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins (NASDAQ:INCY) - Seeking Alpha
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Finviz
Incyte's Monjuvi poised for first-line DLBCL expansion after pivotal study win - FirstWord Pharma
Incyte (NASDAQ:INCY) Price Target Raised to $94.00 - MarketBeat
Incyte reports positive results in late stage trial of lymphoma drug - Delaware Business Now
Positive top-line results for Incyte’s tafasitamab in DLBCL - The Pharma Letter
Spotlight On: Incyte's win in first-line DLBCL points to incremental growth opportunity for Monjuvi - FirstWord Pharma
Incyte stock rises as Stifel reiterates Buy rating on positive trial data - Investing.com India
Why Is Incyte Stock Gaining Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's blood cancer therapy slows disease progression in trial - Reuters
The Bull Case For Incyte (INCY) Could Change Following Positive frontMIND Phase 3 DLBCL Results - simplywall.st
Incyte (INCY) Achieves Phase 3 Success with Tafasitamab in Lymph - GuruFocus
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com - Investing.com Canada
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma - BioSpace
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
2.76%
자본화:
|
볼륨(24시간):